Examining the Use of Three Dimensional Ultrasound in the Assessment of Vascular Pathologies (3D-US)
Primary Purpose
PAD - Peripheral Arterial Disease, Vascular Diseases, Wounds
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
PIUR tUS Imaging System
Sponsored by
About this trial
This is an interventional treatment trial for PAD - Peripheral Arterial Disease
Eligibility Criteria
Inclusion Criteria:
- Age 18 years of age or older
- Suspected vascular insufficiency that requires ultrasound evaluation
- Subject is able to sign a consent form
- Scheduled ultrasound testing at the wound center to evaluate vasculature
Exclusion Criteria:
- Younger than 18 years old
- Subject is not scheduled to have ultrasound testing at the wound center
- Subject is unable to or refuses to consent to participate
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
3D-US
Standard US
Arm Description
These subjects will have a 3D rendering of their vascular testing shown to them.
These subjects will be shown a hand drawn sketch of the results of the vascular testing.
Outcomes
Primary Outcome Measures
30 Day re-admission
The primary endpoint of the study will be the treatment outcomes for the patients. We will review readmission rates (30 days from the day of the ultrasound) as well as compliance to first follow-up appointment after the ultrasound of interventional cohort. These endpoints will be compared to those of a historical cohort of persons who were treated for similar pathologies in the past.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05134311
Brief Title
Examining the Use of Three Dimensional Ultrasound in the Assessment of Vascular Pathologies
Acronym
3D-US
Official Title
Examining the Use of Three Dimensional Ultrasound in the Assessment of Vascular Pathologies
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
February 1, 2024 (Anticipated)
Primary Completion Date
September 1, 2025 (Anticipated)
Study Completion Date
September 1, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwell Health
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The ability to have a visual aid to depict areas of vascular disease that are affecting the patient's health can help in patient comprehension of the problem. This comprehension can lead to better understanding of the issue and increase patient compliance to treatment. The hand drawn sketch produced by the ultrasound technologist provides an inadequate visualization of the vascular insufficiency that is causing the patient's symptoms.
PIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging. This system will provide a low cost and reproducible imaging solution that will be an effective educational tool for people with vascular disease.
Detailed Description
Peripheral arterial disease (PAD) affects approximately 10% of the American population, with 30% to 40% of these patients presenting with claudication symptoms. The prevalence of PAD increases with age and the number of vascular risk factors. More importantly, it is a marker of atherosclerotic disease burden, and is associated with increased mortality from cardiovascular and cerebrovascular causes. There have been recent advances in noninvasive imaging, endovascular approaches for revascularization, and aggressive risk factor management for prevention of cardiac and cerebrovascular complications in PAD.
Ultrasound scanning imaging systems are currently the primary choice for vascular diagnostics. After a standard vascular study, the ultrasound technologist produces a handwritten sketch that highlights various parameters (vessel size and blood flow) throughout the vasculature in question. This sketch is then interpreted by the physician who then assesses and, if need be, performs interventions. This sketch is shown to the patient to better illustrate the vascular insufficiency issues that are affecting the patient. A digital copy of the sketch is also uploaded to the patient portal.
Due to a limited field of action and poor quantification accuracy, patients are often referred for secondary scanning procedures such as computed tomography angiography, magnetic resonance angiography and catheter angiography for more detailed imaging. Referrals delay treatment, expose the patient to potential health risks and pose higher costs to healthcare providers. This can lead to poor patient compliance and avoidable hospital readmissions. This presents a need to improve the rapidity and safety of the diagnosis of vascular conditions in patients to enable rapid treatment of conditions such as peripheral artery disease. There is also a need for cost effective preventative screening and surveillance to enable early intervention, for example, people at high risk of limb amputation.
The PIUR tUS Imaging System has been approved for use in the European Union for over 1 year. Studies performed in Europe have highlighted the system's ability to accurately depict various pathologies in a 3D form. Currently, there is no market equivalent of this technology approved by the FDA for use in the United States. We are conducting this study to determine whether the 3D images created by the device shown to patients can be used as an educational tool to increase patient comprehension of the disease process, compared with the standard of care 2D images. This will be measured in terms of compliance with follow-up appointments and 30-day readmission rates.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PAD - Peripheral Arterial Disease, Vascular Diseases, Wounds
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The primary analysis will compare the proportion of patients readmitted within 30 days of their ultrasound among those who received the 3D ultrasound vs. those who received the 2D ultrasound using a chi-square test. We will also compare the proportion of patients who showed up for their follow-up appointment among those who received the 3D ultrasound vs. those who received the 2D ultrasound using a chi-square test. We will assess for differences in baseline characteristics and factors known to be associated with readmission and compliance with follow-up among the two groups. If warranted, we will adjust for these differences using multivariable regression models.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
270 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
3D-US
Arm Type
Experimental
Arm Description
These subjects will have a 3D rendering of their vascular testing shown to them.
Arm Title
Standard US
Arm Type
No Intervention
Arm Description
These subjects will be shown a hand drawn sketch of the results of the vascular testing.
Intervention Type
Device
Intervention Name(s)
PIUR tUS Imaging System
Intervention Description
PIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging.
Primary Outcome Measure Information:
Title
30 Day re-admission
Description
The primary endpoint of the study will be the treatment outcomes for the patients. We will review readmission rates (30 days from the day of the ultrasound) as well as compliance to first follow-up appointment after the ultrasound of interventional cohort. These endpoints will be compared to those of a historical cohort of persons who were treated for similar pathologies in the past.
Time Frame
30 Days after imaging
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 years of age or older
Suspected vascular insufficiency that requires ultrasound evaluation
Subject is able to sign a consent form
Scheduled ultrasound testing at the wound center to evaluate vasculature
Exclusion Criteria:
Younger than 18 years old
Subject is not scheduled to have ultrasound testing at the wound center
Subject is unable to or refuses to consent to participate
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alisha Oropallo, MD
Phone
516-233-3780
Email
aoropallo@northwell.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alisha Oropallo, MD
Organizational Affiliation
Northwell Health Comprehensive Wound Healing & Hyperbaric Center
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33229220
Citation
Rogers S, Carreira J, Phair A, Olech C, Ghosh J, McCollum C. Comparison Between Below Knee Contrast Enhanced Tomographic 3D Ultrasound and CT, MR or Catheter Angiography for Peripheral Artery Imaging. Eur J Vasc Endovasc Surg. 2021 Mar;61(3):440-446. doi: 10.1016/j.ejvs.2020.10.007. Epub 2020 Nov 20.
Results Reference
background
Links:
URL
https://piurimaging.com/
Description
Company website for 3D imaging device
Learn more about this trial
Examining the Use of Three Dimensional Ultrasound in the Assessment of Vascular Pathologies
We'll reach out to this number within 24 hrs